{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(5)"],"submitter":["Boonkrongsak R"],"funding":["The Children Hospital Foundation, Queen Sirikit National Institute of Child Health"],"pubmed_abstract":["<h4>Objective</h4>The study evaluated the effectiveness of combination therapy with vigabatrin and prednisolone versus vigabatrin alone for treating infantile epileptic spasms syndrome (IESS).<h4>Methods</h4>This single-center, single-blind, randomized trial enrolled infants aged 2-14 months with new-onset IESS, randomly assigned them (1:1) to receive either combination therapy with vigabatrin (100-150 mg/kg/day) and prednisolone (40-60 mg/day) or vigabatrin alone. The primary outcome was sustained spasm remission between days 14 and 42. The trial (ClinicalTrials.gov identifier) was terminated early due to an interim analysis revealing a significant difference between treatment groups.<h4>Results</h4>In all, 17 infants were assigned to combination therapy and 24 to vigabatrin alone. The me"],"journal":["Annals of clinical and translational neurology"],"pagination":["1012-1021"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12093345"],"repository":["biostudies-literature"],"pubmed_title":["Combination Therapy With Vigabatrin and Prednisolone Versus Vigabatrin Alone for Infantile Spasms."],"pmcid":["PMC12093345"],"pubmed_authors":["Boonkrongsak R","Sri-Udomkajorn S","Arya R","Sakpichaisakul K","Suwannachote S","Wittawassamrankul R","Trongkamolchai K"],"additional_accession":[]},"is_claimable":false,"name":"Combination Therapy With Vigabatrin and Prednisolone Versus Vigabatrin Alone for Infantile Spasms.","description":"<h4>Objective</h4>The study evaluated the effectiveness of combination therapy with vigabatrin and prednisolone versus vigabatrin alone for treating infantile epileptic spasms syndrome (IESS).<h4>Methods</h4>This single-center, single-blind, randomized trial enrolled infants aged 2-14 months with new-onset IESS, randomly assigned them (1:1) to receive either combination therapy with vigabatrin (100-150 mg/kg/day) and prednisolone (40-60 mg/day) or vigabatrin alone. The primary outcome was sustained spasm remission between days 14 and 42. The trial (ClinicalTrials.gov identifier) was terminated early due to an interim analysis revealing a significant difference between treatment groups.<h4>Results</h4>In all, 17 infants were assigned to combination therapy and 24 to vigabatrin alone. The me","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-03-27T17:28:05.657Z","creation":"2025-08-31T03:05:45.505Z"},"accession":"S-EPMC12093345","cross_references":{"pubmed":["40116235"],"doi":["10.1002/acn3.70034"]}}